As of Jan 17, 2025, Edwards Lifesciences Corporation Intrinsic Value is $52.3. This suggests it may be overvalued by 25.0% compared to its current price of around $69.8.
As of Jan 17, 2025, Edwards Lifesciences Corporation's Discounted Cash Flow (DCF) valuation estimates its share price at $38.9. This suggests it may be overvalued by 44.2% to its current price of around $69.8, using a discount rate of 9.6% and terminal growth rate of 3.0%.
Edwards Lifesciences Corporation is currently considered overvalued based on its Discounted Cash Flow (DCF) valuation and Relative Valuation, which estimates its share price to be $52.3, compared to a market price of around $69.8. This suggests a potential overvaluation of 25.0%.